Requirement for c-Src Catalytic Activity and the SH3 Domain in Platelet-derived Growth Factor BB and Epidermal Growth Factor Mitogenic Signaling
Open accessThe DOI matches its Crossref record.
Abstract
The Src family protein-tyrosine kinases are required for mitogenic signaling from the platelet-derived growth factor (PDGF), colony stimulating factor-1, and epidermal growth factor (EGF) receptor protein-tyrosine kinases (RPTK) (Twamley-Stein, G. M., Pepperkok, R., Ansorge, W., and Courtneidge, S. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7696-7700; Roche, S., Koegl, M., Barone, M. V., Roussel, M. F., and Courtneidge, S. A.(1995) Mol. Cell. Biol. 15, 1102-1109). In NIH3T3 fibroblasts, c-Src, Fyn, and c-Yes associate with the activated PDGF receptor, are substrates for receptor phosphorylation, and are themselves activated. Src family catalytic function is required for RPTK mitogenic signaling as evidenced by the SH2-dependent dominant negative phenotype exhibited by kinase-inactive Src and Fyn mutants (Twamley-Stein, G. M., Pepperkok, R., Ansorge, W., and Courtneidge, S. A.(1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7696-7700). Here, we have generated clonal Src- murine fibroblast cell lines overexpressing various murine c-Src mutants and studied the effect of these mutant Src proteins on PDGF- and EGF-induced mitogenesis. Two c-Src SH3 domain mutants, Y133F and Y138F, each inhibited PDGF BB- and EGF-induced DNA synthesis in quiescent cells. This demonstrates an involvement of the Src SH3 domain in PDGFbeta and EGF receptor mitogenic signaling. Since both Tyr-133 and Tyr-138 are located on the ligand binding surface of the SH3 domain, these results suggest that the c-Src SH3 domain is required for PDGF and EGF mitogenic signaling. The dominant negative effect of either single mutant on PDGF receptor signaling was reversed by a second SH2-inactivating mutation. We conclude that the c-Src SH3 domain function requires the SH2 domain in the case of the PDGF receptor, presumably because binding of c-Src to the receptor via its SH2 domain is a prerequisite for the SH3 domain function. In contrast, SH2 function is apparently not essential for the SH3 function in EGF receptor signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES
Thomas, S. M., & Brugge, J. S. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,498
Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability
Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., & Cheresh, D. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80221-x · Cited by 813
Src family kinases are required for integrin but not PDGFR signal transduction
Klinghoffer, R. A., Sachsenmaier, C., Cooper, J. A., & Soriano, P. (1999) · The EMBO Journal · doi:10.1093/emboj/18.9.2459 · Cited by 731
Src in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 683
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
Bowman, T., Broome, M. A., Sinibaldi, D., Wharton, W., Pledger, W. J., Sedivy, J. M., Irby, R., Yeatman, T., Courtneidge, S. A., & Jove, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131568898 · Cited by 488
Self-citationRAFTK/Pyk2-mediated cellular signalling
Avraham, H., Park, S.-Y., Schinkmann, K., & Avraham, S. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(99)00076-5 · Cited by 456
The interplay between Src family kinases and receptor tyrosine kinases
Bromann, P. A., Korkaya, H., & Courtneidge, S. A. (2004) · Oncogene · doi:10.1038/sj.onc.1208079 · Cited by 454
Schlaepfer, D. D., Broome, M. A., & Hunter, T. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1702 · Cited by 436
Self-citationPlattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A., & Pendergast, A. M. (1999) · Genes & Development · doi:10.1101/gad.13.18.2400 · Cited by 427
Src Is the Kinase of the Helicobacter pylori CagA Protein in Vitro and in Vivo
Selbach, M., Moese, S., Hauck, C. R., Meyer, T. F., & Backert, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100754200 · Cited by 415
Integrin and Growth Factor Receptor Crosstalk
Eliceiri, B. P. (2001) · Circulation Research · doi:10.1161/hh2401.101084 · Cited by 395
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
Src Family Tyrosine Kinases and Growth Factor Signaling
Abram, C. L., & Courtneidge, S. A. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4732 · Cited by 391
Regulation of Btk Function by a Major Autophosphorylation Site Within the SH3 Domain
Park, H., Wahl, M. I., Afar, D. E. H., Turck, C. W., Rawlings, D. J., Tam, C., Scharenberg, A. M., Kinet, J.-P., & Witte, O. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80417-3 · Cited by 323
Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src−/− mutant mice
Schwartzberg, P. L., Xing, L., Hoffmann, O., Lowell, C. A., Garrett, L., Boyce, B. F., & Varmus, H. E. (1997) · Genes & Development · doi:10.1101/gad.11.21.2835 · Cited by 268
Bourguignon, L. W., Zhu, H., Shao, L., & Chen, Y.-W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006498200 · Cited by 262
Selbach, M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg050 · Cited by 258
Sandilands, E., Cans, C., Fincham, V. J., Brunton, V. G., Mellor, H., Prendergast, G. C., Norman, J. C., Superti-Furga, G., & Frame, M. C. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.09.019 · Cited by 256
Yamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., Kato, S., Tomida, S., Suzuki, M., Osada, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.008 · Cited by 249
Karni, R., Jove, R., & Levitzki, A. (1999) · Oncogene · doi:10.1038/sj.onc.1202835 · Cited by 242
“…matrix to regulate normal cell growth and cell movement (Parsons and Parsons, 1997; Erpel and Courtneidge, 1995). pp60c-Src (c-Src) has been shown to associate directly with the platelet derived growth factor receptor (PDGFR) (Broome and Hunter, 1996) and CSF-1 receptor (Courtneidge et al., 1993).”
BackgroundThe c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Rahimi, N., Hung, W., Tremblay, E., Saulnier, R., & Elliott, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33714 · Cited by 160
Jones, R. J., Avizienyte, E., Wyke, A. W., Owens, D. W., Brunton, V. G., & Frame, M. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600594 · Cited by 80
“Specifically, c-Src is required for platelet-derived growth factor (PDGF)-induced mitogenesis (Roche et al, 1995; Twamley et al, 1993), most likely via its induction of a Stat3/c-Myc pathway (Barone and Courtneidge, 1995; Broome and Hunter, 1996; Wang et al, 2000b; Bowman et al, 2001).”
BackgroundNikolovska, K., Seidler, U. E., & Stock, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.899286 · Cited by 32
Cyclin E and cyclin A are likely targets of Src for PDGF‐induced DNA synthesis in fibroblasts
Furstoss, O., Manes, G., & Roche, S. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03120-4 · Cited by 13
Metadata
- Authors
- Broome, M. A., & Hunter, T.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-07
- Volume
- 271
- Issue
- 28
- Pages
- 16798-16806
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2003023514
- Cited by
- 136
- References
- 0
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.